KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for TherapeuticsMD (TXMD) over the last 15 years, with Q2 2025 value amounting to $1000.0.

  • TherapeuticsMD's Share-based Compensation fell 9895.83% to $1000.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $48000.0, marking a year-over-year decrease of 8651.69%. This contributed to the annual value of $264000.0 for FY2024, which is 7922.9% down from last year.
  • Per TherapeuticsMD's latest filing, its Share-based Compensation stood at $1000.0 for Q2 2025, which was down 9895.83% from $23000.0 recorded in Q1 2025.
  • Over the past 5 years, TherapeuticsMD's Share-based Compensation peaked at $7.3 million during Q3 2021, and registered a low of $1000.0 during Q2 2025.
  • For the 5-year period, TherapeuticsMD's Share-based Compensation averaged around $1.7 million, with its median value being $460500.0 (2023).
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 14226.57% in 2021, then crashed by 9895.83% in 2025.
  • Over the past 5 years, TherapeuticsMD's Share-based Compensation (Quarter) stood at $5.3 million in 2021, then crashed by 43.42% to $3.0 million in 2022, then plummeted by 96.15% to $116000.0 in 2023, then plummeted by 79.31% to $24000.0 in 2024, then plummeted by 95.83% to $1000.0 in 2025.
  • Its Share-based Compensation stands at $1000.0 for Q2 2025, versus $23000.0 for Q1 2025 and $24000.0 for Q4 2024.